Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples

British Journal of Cancer

Volumn 113, Issue 2, 2015, Pages 268-274

  Thomas, D S ^a   Fourkala, E O ^a   Apostolidou, S ^a   Gunu, R ^a   Ryan, A ^a   Jacobs, I ^a,b   Menon, U ^a   Alderton, W ^c   Gentry Maharaj, A ^a   Timms, J F ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ABCODIA LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYFRA21 1 ANTIGEN; UNCLASSIFIED DRUG; ANTIGEN CYFRA21.1; CYTOKERATIN 19; TUMOR ANTIGEN;

ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; BODY MASS; CANCER CONTROL; CANCER SCREENING; CASE CONTROL STUDY; COLORECTAL CANCER; COLORECTAL CARCINOMA; HORMONE SUBSTITUTION; INTERNATIONAL CLASSIFICATION OF DISEASES; INTESTINE CANCER; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; SCREENING; SMOKING; SOCIAL CARE; ADULT; AGED; BLOOD; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; FEMALE; HUMAN; LONGITUDINAL STUDY; MIDDLE AGED;

ADULT; AGED; ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; KERATIN-19; LONGITUDINAL STUDIES; MIDDLE AGED;

EID: 84937073201     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.202     Document Type: Article

References (48)

1. Alexander JC, Silverman NA, Chretien PB (1976) Effect of age and cigarette smoking on carcinoembryonic antigen levels. JAMA 235(18): 1975-1979.
2. Allison JE, Feldman R, Tekawa IS (1990) Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Longterm follow-up in a large group practice setting. Ann Intern Med 112(5): 328-333.
3. Allison JE, Tekawa IS, Ransom LJ, Adrain AL (1996) A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 334(3): 155-159.
4. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J (2010) Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375(9726): 1624-1633.
5. Barak V, Goike H, Panaretakis KW, Einarsson R (2004) Clinical utility of cytokeratins as tumor markers. Clin Biochem 37(7): 529-540.
6. Buchen L (2011) Cancer: missing the mark. Nature 471(7339): 428-432.
7. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR (2010) Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59(5): 666-689.
8. Chevinsky AH (1991) CEA in tumors of other than colorectal origin. Semin Surg Oncol 7(3): 162-166.
9. Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castanos-Velez E, Blumenstein BA, Rosch T, Osborn N, Snover D, Day RW, Ransohoff DF (2013) Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63(2): 317-325.
10. CRUK (2014) Bowel cancer incidence statistics. Available at http://www. cancerresearchuk. org/cancer-info/cancerstats/types/bowel/incidence/ukbowel-cancer-incidence-statistics.
11. Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousova M, Holubec L, Sturgeon C (2014) Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer 134(11): 2513-2522.
12. Fourkala EO, Burnell M, Cox C, Ryan A, Salter LC, Gentry-Maharaj A, Parmar M, Jacobs I, Menon U (2014) Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ Open 4(9): e005400.
13. Gill MD, Bramble MG, Rees CJ, Lee TJ, Bradburn DM, Mills SJ (2012) Comparison of screen-detected and interval colorectal cancers in the Bowel Cancer Screening Programme. Br J Cancer 107(3): 417-421.
14. Goslin R, O'Brien MJ, Steele G, Mayer R, Wilson R, Corson JM, Zamcheck N (1981) Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. Am J Med 71(2): 246-253.
15. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsene D, Boutreux S, Tichet J, Launoy G (2007) Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 56(2): 210-214.
16. Hammarstrom S (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9(2): 67-81.
17. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348(9040): 1472-1477.
18. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E (2007) Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev; (1): CD001216.
19. Holme O, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G (2013) Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev 9: CD009259.
20. Imperiale TF, Ransohoff DF, Itzkowitz SH (2014a) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 371(2): 187-188.
21. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM (2014b) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370(14): 1287-1297.
22. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME (2004) Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351(26): 2704-2714.
23. Johnson DA, Barclay RL, Mergener K, Weiss G, Konig T, Beck J, Potter NT (2014) Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLoS One 9(6): e98238.
24. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O (1996) Randomised study of screening for colorectal cancer with faecal-occultblood test. Lancet 348(9040): 1467-1471.
25. Ladd JJ, Busald T, Johnson MM, Zhang Q, Pitteri SJ, Wang H, Brenner DE, Lampe PD, Kucherlapati R, Feng Z, Prentice RL, Hanash SM (2012) Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prev Res (Phila) 5(4): 655-664.
26. Lee JH (2013) Clinical usefulness of serum CYFRA 21-1 in patients with colorectal cancer. Nucl Med Mol Imaging 47(3): 181-187.
27. Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014) Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and metaanalysis. Ann Intern Med 160(3): 171.
28. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5): 1570-1595.
29. Lindholm E, Brevinge H, Haglind E (2008) Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 95(8): 1029-1036.
30. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast Jr RC (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33): 5313-5327.
31. Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C (2012) Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 61(10): 1439-1446.
32. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328(19): 1365-1371.
33. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10(4): 327-340.
34. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Skates S, Parmar M, Jacobs I (2008) Recruitment to multicentre trials-lessons from UKCTOCS: descriptive study. BMJ 337: a2079.
35. Molina R, Agusti C, Filella X, Jo J, Joseph J, Gimenez N, Ballesta AM (1994) Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumour Biol 15(6): 318-325.
36. NCIN (2010) National Cancer Intelligence Network-Routes to Diagnosis, Data Briefing. Available at http://www. ncin. org. uk/publications/data- briefings/routes-to-diagnosis. aspx.
37. Palmqvist R, Engaras B, Lindmark G, Hallmans G, Tavelin B, Nilsson O, Hammarstrom S, Hafstrom L (2003) Prediagnostic levels of carcinoembryonic antigen and CA 242 in colorectal cancer: a matched case-control study. Dis Colon Rectum 46(11): 1538-1544.
38. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100(20): 1432-1438.
39. Raginel T, Puvinel J, Ferrand O, Bouvier V, Levillain R, Ruiz A, Lantieri O, Launoy G, Guittet L (2013) A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening. Gastroenterology 144(5): 918-925.
40. Ransohoff DF, Lang CA (1997) Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ann Intern Med 126(10): 811-822.
41. Rastel D, Ramaioli A, Cornillie F, Thirion B (1994) CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur J Cancer 30A(5): 601-606.
42. Robb K, Power E, Kralj-Hans I, Edwards R, Vance M, Atkin W, Wardle J (2010) Flexible sigmoidoscopy screening for colorectal cancer: uptake in a population-based pilot programme. J Med Screen 17(2): 75-78.
43. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O'Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD (2012) Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 366(25): 2345-2357.
44. Selby JV, Friedman GD, Quesenberry Jr CP, Weiss NS (1993) Effect of fecal occult blood testing on mortality from colorectal cancer. A case-control study. Ann Intern Med 118(1): 1-6.
45. Taylor DP, Cannon-Albright LA, Sweeney C, Williams MS, Haug PJ, Mitchell JA, Burt RW (2011) Comparison of compliance for colorectal cancer screening and surveillance by colonoscopy based on risk. Genet Med 13(8): 737-743.
46. Wanebo JH, Stearns M, Schwartz MK (1978) Use of CEA as an indicator of early recurrence and as a guide to a selected second-look procedure in patients with colorectal cancer. Ann Surg 188(4): 481-493.
47. Whitlock EP, Lin J, Liles E, Beil T, Fu R, O'Connor E, Thompson RN, Cardenas T (2008) Screening for Colorectal Cancer: An Updated Systematic Review. Evidence Synthesis No. 65, Part 1. Agency for Healthcare Research and Quality: Rockville, MD, USA. AHRQ Publication No. 08-05124-EF-1.
48. Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, Karl J (2010) A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res 16(24): 6111-6121.